Last reviewed · How we verify
Piperacillin-tazobactam administered in a standard infusion
Piperacillin-tazobactam administered in a standard infusion is a Small molecule drug developed by CR-CSSS Champlain-Charles-Le Moyne. It is currently FDA-approved.
Piperacillin-tazobactam, marketed by CR-CSSS Champlain-Charles-Le Moyne, is a well-established antibiotic combination used for treating a variety of bacterial infections. The key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. However, the primary risk lies in the potential increase in generic competition following the patent expiry, which could significantly impact market share and revenue.
At a glance
| Generic name | Piperacillin-tazobactam administered in a standard infusion |
|---|---|
| Sponsor | CR-CSSS Champlain-Charles-Le Moyne |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity (PHASE4)
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Are Standard Dosing Regimens of Piperacillin-Tazobactam Suitable in Critically Ill Patients With Open Abdomen and Negative Pressure Wound Therapy? A Population Pharmacokinetic Study.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Piperacillin-tazobactam administered in a standard infusion CI brief — competitive landscape report
- Piperacillin-tazobactam administered in a standard infusion updates RSS · CI watch RSS
- CR-CSSS Champlain-Charles-Le Moyne portfolio CI